Market Research Logo

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016’, provides in depth analysis on Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1)
  • The report reviews Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) Overview
Therapeutics Development
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Stage of Development
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Therapy Area
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Indication
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Companies
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Companies Involved in Therapeutics Development
Baxalta Incorporated
Kyorin Pharmaceutical Co., Ltd.
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Drug Profiles
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxG-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxM-159 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIF-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Dormant Projects
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Featured News & Press Releases
Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
Mar 30, 2016: MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis
Mar 07, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis
Mar 06, 2016: MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas
Feb 22, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology 68th Annual Meeting in Vancouver, Canada
Feb 11, 2016: MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
Feb 07, 2016: MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease
Dec 16, 2015: FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Baxalta Incorporated, H1 2016
Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report